Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.45 |
| ▸ | RORC | P51449 | 8/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19252178 | 0.83 | CA2 (0.71) | CA2CA9CA1CA12MAPT | |
| SCHEMBL19252182 | 0.81 | CA2 (1.00) | CA2CA9CA1CA12MAPT | |
| SCHEMBL10294706 | 0.80 | PSIP1 (0.52) | CA2CA9CA1CA12MAPT | |
| SCHEMBL9823071 | 0.79 | CA12 (0.65) | CA2CA9CA1CA12MAPT | |
| SCHEMBL10430120 | 0.79 | CA12 (0.65) | CA2CA9CA1CA12MAPT | |
| SCHEMBL10430061 | 0.77 | CA2 (0.63) | CA2CA9CA1CA12MAPT | |
| SCHEMBL25226235 | 0.75 | CA2 (0.59) | CA2CA9CA1CA12MAPT | |
| SCHEMBL10455034 | 0.74 | PSIP1 (0.74) | CA2GAAPSIP1 | |
| SCHEMBL8892467 | 0.74 | CA12 (0.59) | CA2CA9CA1CA12MAPT | |
| SCHEMBL10822863 | 0.73 | GAA (0.48) | MAPTADAM17GAAPSIP1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20220315564-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA2 3501/4885CA9 3772/4885CA1 2828/4885 |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA2 3501/4885CA9 3772/4885CA1 2828/4885 |
| US-20220315564-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA2 3501/4885CA9 3772/4885CA1 2828/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA2 3501/4885CA9 3772/4885CA1 2828/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CA2 2753/4885CA9 2810/4885CA1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.